These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8679054)

  • 1. Synthesis of a series of cytotoxic 2-acyl-1,2-dihydroellipticines which inhibit topoisomerase II.
    Devraj R; Jurayj J; Fernandez JA; Barrett JF; Cushman M
    Anticancer Drug Des; 1996 Jun; 11(4):311-24. PubMed ID: 8679054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity.
    Kim JS; Rhee HK; Park HJ; Lee IK; Lee SK; Suh ME; Lee HJ; Ryu CK; Choo HY
    Bioorg Med Chem; 2007 Jan; 15(1):451-7. PubMed ID: 17035025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
    Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
    Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
    Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
    Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
    Kim MY; Duan W; Gleason-Guzman M; Hurley LH
    J Med Chem; 2003 Feb; 46(4):571-83. PubMed ID: 12570378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
    Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
    J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors.
    Kamal A; Atchison K; Daneshtalab M; Micetich RG
    Anticancer Drug Des; 1995 Oct; 10(7):545-54. PubMed ID: 7495478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel isoellipticine derivatives and salts.
    Miller CM; O'Sullivan EC; Devine KJ; McCarthy FO
    Org Biomol Chem; 2012 Oct; 10(39):7912-21. PubMed ID: 22940706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.
    Fossé P; René B; Charra M; Paoletti C; Saucier JM
    Mol Pharmacol; 1992 Oct; 42(4):590-5. PubMed ID: 1331751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors.
    Guan J; Zhu XK; Tachibana Y; Bastow KF; Brossi A; Hamel E; Lee KH
    J Med Chem; 1998 May; 41(11):1956-61. PubMed ID: 9599244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
    Cline SD; Macdonald TL; Osheroff N
    Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
    J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of bengacarboline derivatives.
    Pouilhès A; Kouklovsky C; Langlois Y; Baltaze JP; Vispé S; Annereau JP; Barret JM; Kruczynski A; Bailly C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1212-6. PubMed ID: 18083028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates.
    Devraj R; Barrett JF; Fernandez JA; Katzenellenbogen JA; Cushman M
    J Med Chem; 1996 Aug; 39(17):3367-74. PubMed ID: 8765520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
    Zhao R; al-Said NH; Sternbach DL; Lown JW
    J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition by ellipticine derivatives of the reactions catalysed by the topoisomerases: preferential inhibition of topoisomerase II].
    Douc-Rasy S; Multon E; Kayser A; Riou G
    C R Seances Acad Sci III; 1983; 296(19):899-904. PubMed ID: 6311366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong BS; Jeong TC; Lee CS; Lee ES
    Bioorg Med Chem; 2007 Jul; 15(13):4351-9. PubMed ID: 17493824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA binding ellipticine analogues: synthesis, biological evaluation, and structure-activity relationships.
    Ferlin MG; Marzano C; Gandin V; Dall'Acqua S; Dalla Via L
    ChemMedChem; 2009 Mar; 4(3):363-77. PubMed ID: 19197924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
    Fossé P; Charra M; Paoletti C; Saucier JM; René B
    Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1.
    Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R
    Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.